TGFB2 and cancer: Furthermore, a well known downstream target of Tgf-β2 signaling and biomarker for cancer risk, Plasminogen Activator-1 (Serpine1) was significantly affected by Sfrp1 loss (F1,19=4.35; P<0.05) and the HFD (F1,19=9.55; P<0.01), but there was no interaction between these two main effects (F1,19=2.09; P>0.05).